RedHill Biopharma
21 Ha’arba’a Street
Tel-Aviv
64739
United States
Tel: 972-0-3-541-3131
Fax: 972-0-3-541-3144
Website: http://www.redhillbio.com/
Email: info@redhillbio.com
367 articles with RedHill Biopharma
-
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
6/21/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib [1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum 2021.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
RedHill Biopharma to Present at the BIO Digital International Convention
6/9/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention, taking place June 14-18, 2021.
-
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
6/7/2021
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464
-
RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
5/27/2021
Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance[i] of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021
5/24/2021
Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms
-
RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021
5/21/2021
New Travelers' Diarrhea (TD) severity classification tool, developed with the University of Texas Houston School of Public Health, provides clear separation of clinical severity categories and prognostic information for TD resolution with potential utility in clinical practice
-
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
5/20/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021 .
-
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
-
Please check out the biopharma industry's COVID-19 stories that are trending for April 13, 2021.
-
Clinical Catch-Up: April 5-9
4/12/2021
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more. -
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
4/9/2021
Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients
-
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
-
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
3/22/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has acted on a request to provide opaganib[1] treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.
-
RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
3/18/2021
Financials : Full year 2020 net revenues of approximately $64 million , with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021 Planned commercial operational breakeven by the end of 2021
-
RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
3/11/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights on Thursday, March 18, 2021 .
-
RedHill to Present at Upcoming Conferences in March
3/5/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March:
-
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares
3/1/2021
RedHill Biopharma Ltd . (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,250,000
-
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
2/23/2021
Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. study activities expected to expand the study to a total of 8 countries and approximately 40 recruiting sites; Top-line results expected in the second quarter